Investor Presentaiton

1H FY24 - Financial Performance Core growth rebounding on healthy demand environment 1H/FY24 Consolidated Financials Comments [*Crore] 1H/FY24 2 1H/FY23 1 Revenues 2,406 3,115 Gross Margins 51.6% 56.3% EBITDA 356 903 Y-o-Y -23% -470bps -61% % to Revenues 14.8% 29.0% -1420bps PBT 95 684 -86% Net Profit 62 484 -87% ■ Revenues: 2,406 Cr, declined 23% YoY, impacted by particularly strong CDMO-Synthesis revenues in base year, partly off-set by improved performance in API and FDF segment Underlying revenues increased by 14% ex-large PO supplies ■ Gross Margins: 51.6%, decreased by 470 bps YoY due to change in share from the business divisions ■ EBITDA : 356 Cr, decreased by 61% YoY % to Revenues 2.6% 15.5% ◉ EBITDA Margins: 14.8%, due to negative operating leverage EPS 1.1 9.0 -88% ■ Net Profits: 62 Cr 1H/FY24 1H/FY23 Y-o-Y Operating Cash flow Capex 474 243 95% 385 416 -7% Net Debt-to-EBITDA 1.9x 1.3x 46% ROCE 11.4% 22.7% -11.3%pts Capex nearly in-line; as we continue to deliver on key projects ■ ROCE declined on higher CDMO base effect, negative leverage and continued strong capital deployment 1 2 14 FY23 financials information is based on material Purchase Order supplies to Big Pharma, that was completed on Dec-22 H1 FY24 results includes 1) Cell & Gene related spends of 6 Cr under R&D expenses, 2) ImmunoACT share of loss 3.4 Cr and 3) LSPL Unit 2 expenses 7 Cr Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation